Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Federation Francophone de Cancerologie Digestive
- Target Recruit Count
- 106
- Registration Number
- NCT03719924
- Locations
- 🇫🇷
Ch Perpignan, Perpignan, France
🇫🇷Chu Rouen, Rouen, France
🇫🇷Chu de Poitiers, Poitiers, France
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 321
- Registration Number
- NCT03715933
- Locations
- 🇺🇸
Precision NextGen Oncology and Research, Beverly Hills, California, United States
🇺🇸University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States
The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03711240
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT03709680
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03703063
- Locations
- 🇺🇸
Virginia mason medical Center, Seattle, Washington, United States
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT03702985
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- David Bajor, MD
- Target Recruit Count
- 49
- Registration Number
- NCT03699319
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
9-ING-41 in Patients with Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT03678883
- Locations
- 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇪🇸Hospital Clinico U San Carlos (HSC), Madrid, Spain
🇪🇸START Madrid-HM CIOCC Hospital Universitario, Madrid, Spain
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
- Conditions
- Interventions
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 92
- Registration Number
- NCT03678428
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 120
- Registration Number
- NCT03668418
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.